Universitätsklinikum des Saarlandes – Homburg/Saar, Klinik für Urologie und Kinderurologie

The department is conducting studies that explore innovative therapies for Transthyretin Amyloid Cardiomyopathy, advanced atherosclerotic disease, and pulmonary hypertension linked to interstitial lung disease, aiming to improve heart function and reduce cardiovascular events.

• Evaluation of novel agents targeting amyloid deposits in the heart
• Assessment of anti‑inflammatory drugs for atherosclerosis with chronic kidney disease
• Investigation of inhaled treatments for pulmonary hypertension associated with lung fibrosis

Universitätsklinikum des Saarlandes collaborates with seven investigators to advance cardiovascular care through these trials.

Research at the site focuses on rare genetic conditions such as Hereditary Hemorrhagic Telangiectasia and growth disorders like hypochondroplasia, evaluating safety and efficacy of targeted molecules to address disease manifestations early in life.

• Safety assessment of ALN-6400 in adults with HHT
• Growth outcomes with vosoritide in infants with hypochondroplasia
• Exploration of therapies for Turner syndrome‑related complications

The clinical program leverages multidisciplinary expertise to improve outcomes for pediatric and hereditary disorders.

The urology department collaborates on ocular studies targeting severe corneal injuries, specifically testing cenegermin ophthalmic solution to accelerate healing of persistent epithelial defects.

• Randomized trial of cenegermin versus vehicle for corneal epithelial repair
• Evaluation of patient‑reported visual function improvements

These eye‑focused investigations complement the site’s broader commitment to rare disease research.

Studies address blood‑related malignancies, including acute myeloid leukemia, chronic lymphocytic leukemia, and follicular lymphoma, with the goal of testing new drug combinations to enhance remission rates and survival.

• Combination of revumenib, azacitidine, and venetoclax in NPM1‑mutated AML
• BGB‑16673 versus standard regimens in CLL/SLL after BTK and BCL‑2 inhibitor exposure
• Odronextamab combined with chemotherapy for untreated follicular lymphoma

The trials involve a coordinated effort of seven investigators to bring novel hematologic therapies to patients.

Ongoing research evaluates immunomodulatory approaches for conditions such as chronic graft‑versus‑host disease and immune‑mediated cancers, seeking to balance efficacy with tolerability.

• Axatilimab plus corticosteroids as first‑line treatment for chronic GVHD
• Rilvegostomig combined with chemotherapy versus pembrolizumab in PD‑L1‑positive NSCLC
• MK‑2870 assessment in recurrent cervical cancer

These immune‑focused trials reflect the site’s dedication to advancing therapeutic options for complex immune disorders.

The clinic investigates growth‑related disorders, including short stature syndromes, by comparing long‑acting growth hormone analogues with daily formulations to improve linear growth in children.

• Weekly lonapegsomatropin versus daily somatropin in growth‑hormone sufficient short stature
• Impact of vosoritide on linear growth in hypochondroplasia
• Exploratory analyses of bone density outcomes in treated cohorts

Pediatric endocrinology expertise supports these trials aimed at enhancing quality of life for young patients.

A broad oncology portfolio includes trials for prostate, lung, cervical, and metastatic cancers, focusing on targeted agents, immunotherapies, and combination regimens to improve survival and disease control.

• AZD5305 plus new hormonal agents in metastatic castration‑sensitive prostate cancer
• PD‑L1‑positive non‑small cell lung cancer treatment comparisons
• Second‑line therapy evaluation in recurrent or metastatic cervical cancer

The site’s oncology team collaborates across specialties to deliver cutting‑edge cancer research.

Research addresses metabolic liver disease and systemic inflammation, testing agents that may modify disease progression and reduce cardiovascular risk in patients with metabolic dysfunction.

• SYNERGY‑Outcomes master protocol for metabolic dysfunction‑associated steatotic liver disease
• Ziltivekimab trial targeting major adverse cardiovascular events in ASCVD with CKD

These metabolic studies integrate cardiology and hepatology insights to tackle complex disease pathways.

Clinical investigations target pulmonary hypertension linked to interstitial lung disease, evaluating novel inhaled therapies designed to improve exercise capacity and pulmonary hemodynamics.

• Trepostinil Palmitil inhalation powder safety and efficacy trial
• Exercise capacity outcomes with TPIP versus placebo

The trials aim to provide new treatment options for patients with limited respiratory function.

The institution conducts studies on genetic mutations underlying rare diseases, such as short stature homeobox deficiency and Turner syndrome, to assess targeted therapeutic interventions.

• Evaluation of growth therapies in SHOX‑deficiency related short stature
• Genotype‑guided treatment strategies for Turner syndrome complications

Genetic research at the site supports personalized medicine approaches across multiple therapeutic areas.